The purpose of this study is to determine disease-free survival, overall survival, time to progression, regimen-related toxicity and/or treatment-related mortality in patients with hematologic malignancies treated with non-myeloablative chemotherapy followed by allogeneic stem cell transplant.

Allogeneic bone marrow transplantation (BMT) became feasible in the 1960s after elucidation of the Human Leukocyte Antigen (HLA) complex. Since then, the therapy has evolved into an effective treatment for many hematologic disorders. Otherwise incurable malignancies are frequently cured by this approach, with the likelihood of cure ranging from 10% to 85%, depending on the disease and the disease status. The treatment strategy incorporates very large doses of chemotherapy and often radiation to eliminate cancer cells and to immunosuppress the recipient to allow the engraftment of donor cells. Donor cells give rise to hematopoiesis within two to three weeks, rescuing the patient from the effects of high dose therapy. In the ideal situation, immune recovery and recipient-specific tolerance occurs over the following 6-18 months, and the patient is cured of their underlying malignancy, off immunosuppression, with a functionally intact donor-derived immune system. However, complications are common and include fatal organ damage from the effects of high dose chemotherapy, infection, hemorrhage, and, in particular, graft-versus-host disease (GvHD). A realistic estimate of transplant-related mortality in the standard HLA-matched sibling setting is approximately 25%. The risk of treatment-related mortality limits the success and certainly precludes its use in older patients. Thus, new strategies in transplantation are needed.

With the growing understanding that much of the curative potential of allogeneic bone marrow or stem cell transplant (SCT) is from an immune anti-tumor effect of donor cells, known as graft-versus-leukemia (GvL) or graft-versus-tumor (GvT), a new strategy is being employed that shifts the emphasis from high-dose chemo-radiotherapy to donor-derived, immune-mediated anti-tumor therapy. In this approach, patients receive preparative regimens that, while having some anti-tumor activity, are mainly designed to be immunosuppressive enough to allow engraftment of donor stem cells and lymphocytes. Engrafted lymphocytes then mediate a GvL effect; if the GvL effect of the initial transplant is not sufficient, then additional lymphocytes may be infused (achievement of engraftment allows additional lymphocytes to "take" in the recipient without requiring any additional conditioning of the recipient). The lower intensity of the preparative regimen lessens the overall toxicity by minimizing the doses of chemo-radiotherapy. In addition, less intensive preparative regimens may be associated with less GvHD, as much evidence suggests that high-dose therapy contributes to the syndrome of GvHD by causing tissue damage, leading to a cytokine milieu which enhances activation of graft-versus-host (GvH) effector cells. Thus, such an approach may allow the safer use of allogeneic transplants in standard populations and may allow extension of allogeneic transplantation to patients who could not receive standard (myeloablative) transplants because of age or co-morbidities. This protocol investigates a non-myeloablative transplant approach, using fludarabine and cyclophosphamide, to allow engraftment of allogeneic cells, which may then mediate anti-tumor effects.

Inclusion Criteria:

• Age: 18-75 years

• Diseases

  1. Chronic myelogenous leukemia (CML)

     • First chronic phase or later
     • Accelerated phase

  2. Acute myelogenous or lymphoblastic leukemia (AML or ALL)

     • Second or subsequent remission
     • Patients who have failed an autologous PBSC transplant
     • First remission with poor risk features, including, but not limited to: For AML- complex chromosome karyotype, abnormalities of chromosome 5 or 7, 12p-, 13+, 8+, t(9;22), t(11;23) For ALL- t(9;22), t(4;11), t(1;19), myeloid antigen coexpression

  3. Myelodysplastic syndrome (MDS)

  4. Multiple myeloma - high risk myeloma (poor responders, relapse after autologous PBSCT, chromosome 13 abnormalities)

  5. Hodgkin's disease

     • Primary refractory disease
     • Relapsed disease (first relapse or later)
     • Patients who have failed an autologous PBSC transplant

  6. Non-Hodgkin's lymphoma Low grade (by Working Formulation)

     • Relapsed, progressive disease after initial chemotherapy
     • Primary refractory disease or failure to respond (>PR) to initial chemotherapy
     • Patients who have failed an autologous PBSC transplant Intermediate grade (by Working Formulation)
     • Relapsed disease
     • Primary refractory disease or failure to respond (>PR) to initial chemo
     • Mantle cell lymphoma
     • Patients who have failed an autologous PBSC transplant

  7. Chronic lymphocytic leukemia (CLL)

     • Patients newly diagnosed with poor prognostic factors, including CD38 expression, Chromosome 11 or 17 abn
     • T-CLL/PLL
     • Relapsed or progressive disease, or refractory after Fludarabine
     • Patients who have failed an autologous PBSC transplant

• Donor Availability: Six of six matched HLA A, B and DR identical sibling (or parent or child) or 5/6 related donor with single mismatch at Class I antigen (A or B)

• Karnofsky performance status of >70%

• Serum bilirubin <2x upper limit of normal; transaminases <3x normal (unless due to disease)

• 24 hr urine creatinine clearance of >40 ml/min.

• DLCO >50% predicted

• Left ventricular ejection fraction >35%

• No active infection

• Non-pregnant female

• Signed informed consent

• No major organ dysfunction or psychological problems that preclude compliance and completion of the clinical trial.

Exclusion Criteria

• Major organ dysfunction
• Pregnant or lactating female
• Active infection
• Psychological problems that preclude compliance and completion of the clinical trial
• Any other condition, that in the judgement of the investigator, affects participant safety or overall participation

All-Cause Mortality was assessed for up to 15 years post-transplant. Adverse event data was not collected.

Serious Adverse Event data was not collected. Other [Not Including Serious] Adverse Events were not monitored/assessed